Cabozantinib in the treatment of advanced renal cell carcinoma: Design, development, and potential place in the therapy

Paolo Grassi, Elena Verzoni, Raffaele Ratta, Alessia Mennitto, Filippo de Braud, Giuseppe Procopio

Research output: Contribution to journalReview articlepeer-review

Abstract

The treatment of metastatic renal cell carcinoma (mRCC) has markedly improved over the last few years with the introduction of several targeted agents in clinical practice. Nevertheless, either primary or secondary resistance to inhibition of VEGF and mTOR pathways has limited the clinical benefit of these systemic treatments. Recently, a better understanding of the involvement of MET and its ligand HGF in many biological processes made this signaling pathway an attractive therapeutic target in oncology, particularly in mRCC. Herein, we review the development of cabozantinib, a recently approved inhibitor of multiple tyrosine kinase receptors, including MET, VEGFRs, and AXL, which has proven to increase progression-free survival and overall survival when compared to everolimus in mRCC patients who had progressed after VEGFR-targeted therapy. Finally, we discuss the potential role of cabozantinib within the current treatment landscape for mRCC.

Original languageEnglish
Pages (from-to)2167-2172
Number of pages6
JournalDrug Design, Development and Therapy
Volume10
DOIs
Publication statusPublished - Jul 5 2016

Keywords

  • c-Met
  • Cabozantinib
  • Metastatic renal cell carcinoma
  • Targeted therapy
  • VEGF-inhibitor
  • XL-184

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Pharmacology
  • Drug Discovery

Fingerprint Dive into the research topics of 'Cabozantinib in the treatment of advanced renal cell carcinoma: Design, development, and potential place in the therapy'. Together they form a unique fingerprint.

Cite this